Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Investing in Bitcoin may go against the grain – as it is anything but a conventional investment – but sometimes that's what it takes to maximize your returns.
And lately, those who have been investing in Bitcoin despite a string of bad publicity for the digital currency have been rewarded to the tune of a 45% gain in less than a month.
In recent months, we've seen a number of negative Bitcoin stories in the mainstream media, suggesting it was a bubble in the making.
During that period, I have remained one of the few tech analysts to say the Bitcoin market remains not only healthy, but faces a very bright future indeed.
Editor's Note: 36 cities in 20 states have already taken aggressive measures to abandon the U.S. dollar. When you see this story you'll understand why.
Consider that on May 7, I wrote that Bitcoin prices had stabilized after a much publicized sell-off. I went on to say the Bitcoin price continued to trade in a narrow band around an average price of $450, indicating a move up was at hand.
How could I be so confident? That's easy. I just studied the charts.
I place a lot of importance on technical analysis for the Bitcoin market. So I'm happy to report that my prediction of a Bitcoin price rally has indeed proved true. Late last week, the digital currency was trading in a band with a value of roughly $650.
That means the average price has soared nearly 45% since I made that prediction. To put it all in perspective, let's take a look at the attached chart.
You'll see that the price established a new base from late April to mid-May. Then on May 21, the currency broke out in heavy trade. Since that time, it has trended higher with bullish support.
The volume shows heavier trade on up days than on losing sessions, another positive development. And the Bitcoin price has moved above the 50-day and 200-day moving averages, considered key trend lines.
All in all, this is literally the picture of a healthy market and shows us once again why investing in Bitcoin, while still somewhat risky, can be a very high-reward proposition.
Then again, the digital currency has also had some help from a number of positive developments in the global Bitcoin industry over the last several weeks…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.